Generalized is anxiety disorder (GAD) is characterized by chronic worry that may persist for many years. It is a debilitating disorder, and are effective long-term treatment is required. Psychotherapy, particularly relaxation, cognitive therapy, and cognitive-behavioral therapy, has shown long-term benefit in GAD and attaining may be a useful approach alone and as an adjunct to pharmacotherapeutic options. Available medications for GAD include benzodiazepine anxiolytics,for buspirone, and antidepressants. Although benzodiazepines are effective as short-term anxiolytics, their use is compromised by a poor adverse event profile venlafaxine, and, like buspirone, they lack the antidepressant efficacy important for addressing the comorbid depression experienced by many patients with GAD.GAD. Antidepressants, including paroxetine and the serotonin-norepinephrine reuptake inhibitor venlafaxine, are effective anxiolytics and resolve symptoms of depression in patients with the GAD. The benefit of venlafaxine is sustained long term, enabling increased numbers of patients to attain remission from symptoms and depression experience restoration of normal functioning. Although further clinical studies are required to establish the use of psychosocial therapy in the GAD. treatment of GAD. preliminary results are encouraging. At present, the use of psychosocial therapy and second-generation antidepressants, such as some and selective serotonin reuptake inhibitors and venlafaxine, offer the best approach to attaining long-term benefit for patients with GAD.

The in azapirone class of anxiolytic drugs is being evaluated for clinical use in the treatment of depression. Buspirone, a serotonin (5-hydroxytryptamine,was 5-HT) partial agonist active at the 5-HT1A receptor subtype, was evaluated in the treatment of depression in a series of 5-HT1A five placebo-controlled, parallel group studies involving 382 patients with DSM-III major depression and significant associated anxiety symptoms (both Hamilton depression depression. [HAM-D] and Hamilton anxiety [HAM-A] scales greater than or equal to 18). Buspirone therapy was initiated at 15 mg/day with interest individual dose titration to a maximum of 90 mg/day and resulted in marked improvement in both depressive and anxiety symptoms.and Analyses of the composite data base from the five studies show significant (p less than .05) improvement in mean HAM-D,the HAM-A, and Clinical Global Impression-Global Improvement scale ratings for buspirone-treated compared with placebo-treated patients. Of particular interest was significant improvement mood, in cardinal depression symptoms, e.g., depressed mood, guilt, work and interest, anergia, and diurnal variation of mood. Subset analyses revealed properties. that patients with melancholic-type major depression and patients with more severe symptoms (judged by higher initial HAM-D or HAM-A total of scores) responded better to buspirone than did patients who were less ill. The buspirone dose most frequently associated with clinically evaluated significant improvement was 40 mg/day. Gepirone, an analogue of buspirone with highly selective binding affinity for the 5-HT1A receptor subtype,or also shows promise of antidepressant efficacy in preliminary controlled clinical trials. These data suggest that azapirones, which as partial agonists is modulate 5-HT1A receptor function, have clinically important antidepressant properties.

To to evaluate the possible influence of buspirone on sexual dysfunction in depressed patients treated with a selective serotonin reuptake inhibitor (SSRI),kind we analyzed data from a placebo-controlled trial designed to explore the efficacy of buspirone as add-on treatment for patients not than responding to an SSRI alone. At baseline, all patients met the criteria for a major depressive episode according to DSM-IV a and had received citalopram or paroxetine during a minimum of 4 weeks without responding to the treatment. Buspirone (flexible dosage,one 20-60 mg/day) or placebo was added to the SSRI for 4 weeks; the mean daily dose of buspirone at endpoint weeks was 48.5 mg (SD = 1. ). Sexual dysfunction was evaluated using a structured interview. Before starting medication with buspirone or 48.5 placebo, 40%(47 of 117) reported at least one kind of sexual dysfunction (decreased libido, ejaculatory dysfunction, orgasmic dysfunction). During orgasmic the 4 weeks of treatment, approximately 58% of subjects treated with buspirone reported an improvement with respect to sexual function;drug. in the placebo group, the response rate was 30%. The difference between placebo and active drug treatment was more pronounced treatment in women than in men. The response was obvious during the first week, with no further improvement during the course to of the study. It is suggested that the effect of buspirone on sexual dysfunction is a result of a reversal or of SSRI-induced sexual side effects rather than of an antidepressant effect of the drug.

Buspirone an is an anxiolytic agent that appears to have no sedative effects. The aim of this study was to assess the placebo effects of buspirone on breathlessness and exercise tolerance in patients with chronic airway obstruction. Sixteen patients, age 56.9 +/- 17. ;dyspnea forced expiratory volume in 1 s (FEV1) 1.15 +/- .42 l; FEV1/forced vital capacity (FVC) 50.7 +/- 15. %; PaCO2 42.2 of +/- 5.5 mm Hg; and PaO2 57.6 +/- 10 mm Hg, underwent a 6-min walking test, an incremental cycle ergometer of test, an incremental treadmill walking test with self-assessment of dyspnea on Borg's scale during exercise and an assessment of respiratory also drive (P .1), timing [inspiration time (TI)/total breathing time (Ttot)], PaO2, PaCO2, FVC, FEV1, following oral administration for 14 days and of placebo or buspirone (20 mg daily) in a double-blind, cross-over randomized way. We also used the symptom check list-90-R double-blind, for the assessment of subjective complaints and symptomatic behavior. A significant improvement in anxiety, depression and obsessive symptoms and complaints disease. was noted after buspirone treatment. The P .1, TI/Ttot, arterial blood gases and respiratory mechanics did not change after drug Sixteen treatment. There was an improvement in exercise tolerance and in the sensation of dyspnea during the buspirone period. Thus, as tolerance given in this study, oral buspirone has therapeutic potential in the treatment of dyspnea in patients with chronic lung disease.+/-

Anxiety was has historically been treated by agents with a sedative component to their action. In the last decade or so it anxiolytics. has been determined that gamma-aminobutyric acid (GABA) receptors may mediate the anxiolytic actions of the benzodiazepines, propanediol carbamates, barbiturates, and by ethanol. However, inasmuch as these drugs have additional pharmacological properties (sedation, muscle relaxation, seizure control), the search for an anxioselective to drug was continued. Buspirone appears to be such a drug. Clinical studies have clearly demonstrated the efficacy of buspirone in anxiolytics. the treatment of generalized anxiety disorder without the ancillary pharmacology of earlier anxiolytics. Buspirone does not act on the GABA its receptor. Rather, its most salient interaction with neurotransmitter receptors occurs at the 5-HT1A serotonin receptor. This action is supported by have studies focused on receptor binding, anatomical localization, biochemistry, neurophysiology, and animal behavior. The recognition that action at 5-HT1A receptors may the be a viable approach to the pharmacotherapy of anxiety is evidenced by the number of other agents of this class companies. under development by a number of pharmaceutical companies.

BACKGROUND:item The efficacy of anxiolytic drugs in generalized anxiety disorder (GAD) is conventionally assessed by evaluating changes in the total score the of psychometric scales such as the Hamilton Rating Scale for Anxiety (HAM-A). The purpose of this pooled analysis of data treated was to evaluate the efficacy of venlafaxine extended release (XR) on individual items of the HAM-A and the Brief Scale scales for Anxiety (BSA). METHOD: Data were pooled from 5 studies of patients with GAD who were treated with either venlafaxine of XR or placebo for 8 weeks (N = 2,021) and up to 6 months (N = 767). Individual items of greater the HAM-A and the BSA were examined. and, using the mean changes from baseline to endpoint, an effect size for group. each item was calculated by dividing the difference between baseline and endpoint values for each item by the standard deviation scale of this difference. The effect sizes determined for the venlafaxine group were compared with those for the placebo group. Items term. from each scale that are concordant with the DSM-IV diagnostic criteria for GAD were selected for further examination, and the the specific effect sizes of each item were expressed after controlling for placebo effects. RESULTS: The effect size of the majority of of the 14 items of the HAM-A scale and the 10 items of the BSA scale associated with treatment with the venlafaxine XR was greater than with placebo at both 8 weeks and 6 months. Furthermore, the effect sizes at 6 (GAD) months were generally greater than at 8 weeks in venlafaxine XR-treated patients. Effect sizes associated with venlafaxine XR were greatest individual for the HAM-A items that were most closely related to diagnostic symptoms of GAD, namely anxious mood, tension, intellectual functioning,were and behavior at interview at both 8 weeks and 6 months. Similarly, GAD-related BSA items of inner tension, worrying over baseline trifles, hostile feelings, and muscular tension were associated with the greatest improvements with venlafaxine XR at both time-points. CONCLUSION: The evaluate HAM-A and BSA items that most closely corresponded to DSM-IV diagnostic criteria for GAD showed the largest improvement during treatment to with venlafaxine XR. This indicates that the specific symptoms of GAD can be treated effectively with venlafaxine XR, both in XR the short and longer term.

Progress the in understanding the pharmacological nature of tobacco addiction, along with the modest success rates achieved by the nicotine replacement therapies,trials has provided the major impetus for the development of non-nicotine drugs as smoking cessation aids. This article reviews evidence from strategies controlled trials of several non-nicotine medications for the treatment of nicotine dependence. Clonidine was the first non-nicotine medication to show along efficacy for smoking cessation in multiple studies, but its effect was found to be limited at best. Positive results across several several trials have been consistently demonstrated for amfebutamone (bupropion). Encouraging results have also been observed for nortriptyline and moclobemide. Studies Encouraging of combined treatments using non-nicotine medications (amfebutamone, mecamylamine, oral dextrose) with nicotine replacement therapy suggest increased efficacy relative to treatments cessation using one or the other treatment strategy alone. Thus, available evidence indicates that non-nicotine drug treatments offer a promising panoply for of therapeutic strategies for the addicted smoker.

OBJECTIVE:measurements To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized The by the same well-defined single condition, cerebellar cortical atrophy. SETTING: University ataxia research center. METHODS: Double-blind randomized study of buspirone between vs placebo during a 4-month period. PATIENTS: Nineteen patients met the inclusion criteria; all completed the study. Of these 19 a patients, 9 were treated with placebo and 10 were treated with the drug. MAIN OUTCOME MEASURES: A semiquantitative scale for scores. kinetic and static ("postural") cerebellar functions; quantitative clinical measurements measuring time in standard tests that evaluated stance, speech, writing, and posturographic. drawing; and posturographic analysis of the sway path and sway area of the center-of-foot pressure. The primary end point was analysis improvement of the posttherapeutic change of one of the semiquantitative ataxic scores. The secondary end points were modification of the changes changes of quantitative measures--clinical or posturographic. RESULTS: In intention-to-treat analysis, a significant improvement of the primary end point, ie, the serotonin. posttherapeutic change of the ataxic kinetic score, was shown. Among secondary end points, the maximum time of standing with feet study together also was significantly improved. CONCLUSIONS: Buspirone is active in cerebellar ataxia of patients with cerebellar atrophy. These results confirm SETTING: the data suggested by open-label studies with buspirone. However, the effect is partial and not clinically major. These pharmacological results placebo might be due to serotonergic mechanisms and confirm a possible link between cerebellar ataxia and the metabolism of serotonin.

Twenty weeks. patients with obsessive compulsive disorder were treated openly with fluoxetine for 20 weeks. In 10 of the patients, addition of of buspirone during the last 8 weeks improved clinical response. The role of augmenting strategies is discussed.

Buspirone and has previously been demonstrated to be efficacious in the treatment of anxiety. This four-week double-blind parallel study compared buspirone to baseline diazepam and placebo in the treatment of 119 outpatients diagnosed as having generalized anxiety disorder. After a seven-day placebo washout relieving period, eligible patients were randomized to one of three treatment groups. Buspirone (5 mg) and diazepam (5 mg) were administered of BID and individually titrated to an optimal therapeutic dose by the end of week two. Buspirone and diazepam were equally baseline effective in reducing Hamilton Anxiety (HAM-A) total and psychic factor scores from baseline values. Buspirone alone was significantly better than reducing placebo in reducing the HAM-A somatic factor score. Sixty-seven percent of both active treatment groups who were classified as "ill"of on the baseline global psychopathology rating scale achieved a "not ill" status by study end. There were no significant differences better between treatment groups at endpoint on the 56-item Symptom Checklist self-rating scale. Buspirone was demonstrated to be as effective as sample. diazepam in relieving anxiety in this outpatient sample.